|
1
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
al-Kattan K, Sepsas E, Fountain SW and
Townsend ER: Disease recurrence after resection for stage I lung
cancer. Eur J Cardiothorac Surg. 12:380–384. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iwasa T, Okamoto I, Suzuki M, Nakahara T,
Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K:
Radiosensitizing effect of YM155, a novel small-molecule survivin
suppressant, in non-small cell lung cancer cell lines. Clin Cancer
Res. 14:6496–6504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li WL, Lee MR and Cho MY: The small
molecule survivin inhibitor YM155 may be an effective treatment
modality for colon cancer through increasing apoptosis. Biochem
Biophys Res Commun. 471:309–314. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schimmer AD: Inhibitor of apoptosis
proteins: Translating basic knowledge into clinical practice.
Cancer Res. 64:7183–7190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li F and Altieri DC: The cancer
antiapoptosis mouse survivin gene: Characterization of locus and
transcriptional requirements of basal and cell cycle-dependent
expression. Cancer Res. 59:3143–3151. 1999.PubMed/NCBI
|
|
11
|
Chantalat L, Skoufias DA, Kleman JP, Jung
B, Dideberg O and Margolis RL: Crystal structure of human survivin
reveals a bow tie-shaped dimer with two unusual alpha-helical
extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chae YC, Angelin A, Lisanti S, Kossenkov
AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner
S, et al: Landscape of the mitochondrial Hsp90 metabolome in
tumours. Nat Commun. 4:21392013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheung CH, Huang CC, Tsai FY, Lee JY,
Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY: Survivin -
biology and potential as a therapeutic target in oncology. Onco
Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tazo Y, Hara A, Onda T and Saegusa M:
Bifunctional roles of survivin-Delta Ex3 and survivin-2B for
susceptibility to apoptosis in endometrial carcinomas. J Cancer Res
Clin. 140:2027–2037. 2014. View Article : Google Scholar
|
|
15
|
Liu YB, Gao X, Deeb D, Brigolin C, Zhang
Y, Shaw J, Pindolia K and Gautam SC: Ubiquitin-proteasomal
degradation of antiapoptotic survivin facilitates induction of
apoptosis in prostate cancer cells by pristimerin. Int J Oncol.
45:1735–1741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dohi T, Beltrami E, Wall NR, Plescia J and
Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsuneki M and Madri JA: CD44 regulation of
endothelial cell proliferation and apoptosis via modulation of CD31
and VE-cadherin expression. J Biol Chem. 289:5357–5370. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ikeguchi M, Liu J and Kaibara N:
Expression of survivin mRNA and protein in gastric cancer cell line
(MKN-45) during cisplatin treatment. Apoptosis. 7:23–29. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng WE, Chen H, Yuan SF, Wu LL, Zhang W,
Sun HY and Chen WJ: Overexpression of βIII-tubulin and survivin
associated with drug resistance to docetaxel-based chemotherapy in
advanced gastric cancer. J BUON. 17:284–290. 2012.PubMed/NCBI
|
|
21
|
Shen X, Zheng JY, Shi H, Zhang Z and Wang
WZ: Survivin knockdown enhances gastric cancer cell sensitivity to
radiation and chemotherapy in vitro and in nude mice. Am J Med Sci.
344:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guvenc H, Pavlyukov MS, Joshi K, Kurt H,
Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin
D, et al: Impairment of glioma stem cell survival and growth by a
novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res.
19:631–642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garg H, Suri P, Gupta JC, Talwar GP and
Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell
Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lens SM, Wolthuis RM, Klompmaker R, Kauw
J, Agami R, Brummelkamp T, Kops G and Medema RH: Survivin is
required for a sustained spindle checkpoint arrest in response to
lack of tension. EMBO J. 22:2934–2947. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao J, Tenev T, Martins LM, Downward J
and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin
degradation in a cell cycle-dependent manner. J Cell Sci.
113:4363–4371. 2000.PubMed/NCBI
|
|
26
|
Giodini A, Kallio MJ, Wall NR, Gorbsky GJ,
Tognin S, Marchisio PC, Symons M and Altieri DC: Regulation of
microtubule stability and mitotic progression by survivin. Cancer
Res. 62:2462–2467. 2002.PubMed/NCBI
|
|
27
|
Fangusaro JR, Caldas H, Jiang Y and Altura
RA: Survivin: An inhibitor of apoptosis in pediatric cancer.
Pediatr Blood Cancer. 47:4–13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altieri DC: Survivin in apoptosis control
and cell cycle regulation in cancer. Prog Cell Cycle Res.
5:447–452. 2003.PubMed/NCBI
|
|
29
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Véquaud E, Desplanques G, Jézéquel P, Juin
P and Barillé-Nion S: Survivin contributes to DNA repair by
homologous recombination in breast cancer cells. Breast Cancer Res
Treat. 155:53–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mirza A, McGuirk M, Hockenberry TN, Wu Q,
Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al:
Human survivin is negatively regulated by wild-type p53 and
participates in p53-dependent apoptotic pathway. Oncogene.
21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang M, Li B, Liu J and Sun H: Protection
effect of survivin protein overexpression on acute myocardial
infarction in rats. Int J Clin Exp Med. 8:12995–13000.
2015.PubMed/NCBI
|
|
33
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
34
|
Li F, Ackermann EJ, Bennett CF, Rothermel
AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC:
Pleiotropic cell-division defects and apoptosis induced by
interference with survivin function. Nat Cell Biol. 1:461–466.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wheatley SP: The functional repertoire of
survivin's tails. Cell Cycle. 14:261–268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dohi T, Xia F and Altieri DC:
Compartmentalized phosphorylation of IAP by protein kinase A
regulates cytoprotection. Mol Cell. 27:17–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hagenbuchner J, Kuznetsov AV, Obexer P and
Ausserlechner MJ: BIRC5/survivin enhances aerobic glycolysis and
drug resistance by altered regulation of the mitochondrial
fusion/fission machinery. Oncogene. 32:4748–4757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schulenburg A, Blatt K, Cerny-Reiterer S,
Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC and Valent
P: Cancer stem cells in basic science and in translational
oncology: Can we translate into clinical application? J Hematol
Oncol. 8:162015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stoica G, Lungu G, Martini-Stoica H,
Waghela S, Levine J and Smith R III: Identification of cancer stem
cells in dog glioblastoma. Vet Pathol. 46:391–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hensley ML, Schuchter LM, Lindley C,
Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ
Jr, Mitchell RB, et al: American Society of Clinical Oncology
clinical practice guidelines for the use of chemotherapy and
radiotherapy protectants. J Clin Oncol. 17:3333–3355. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Walker MD, Alexander E Jr, Hunt WE,
MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G,
Ransohoff J, Wilson CB, et al: Evaluation of BCNU and/or
radiotherapy in the treatment of anaplastic gliomas. A cooperative
clinical trial. J Neurosurg. 49:333–343. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dick JE: Looking ahead in cancer stem cell
research. Nat Biotechnol. 27:44–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab
T and Lin J: STAT3 signaling pathway is necessary for cell survival
and tumorsphere forming capacity in
ALDH+/CD133+ stem cell-like human colon
cancer cells. Biochem Biophys Res Commun. 416:246–251. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vermeulen L, De Sousa E, Melo F, van der
Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M,
Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem
cells and is regulated by the microenvironment. Nat Cell Biol.
12:468–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mao J, Fan S, Ma W, Fan P, Wang B, Zhang
J, Wang H, Tang B, Zhang Q, Yu X, et al: Roles of Wnt/β-catenin
signaling in the gastric cancer stem cells proliferation and
salinomycin treatment. Cell Death Dis. 5:e10392014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cai C and Zhu X: The Wnt/β-catenin pathway
regulates self-renewal of cancer stem-like cells in human gastric
cancer. Mol Med Rep. 5:1191–1196. 2012.PubMed/NCBI
|
|
51
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Blagosklonny MV: Cancer stem cell and
cancer stemloids: From biology to therapy. Cancer Biol Ther.
6:1684–1690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M
and Sasamata M: Broad spectrum and potent antitumor activities of
YM155, a novel small-molecule survivin suppressant, in a wide
variety of human cancer cell lines and xenograft models. Cancer
Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chang BH, Johnson K, LaTocha D, Rowley JS,
Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, et
al: YM155 potently kills acute lymphoblastic leukemia cells through
activation of the DNA damage pathway. J Hematol Oncol. 8:392015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cheng XJ, Lin JC, Ding YF, Zhu L, Ye J and
Tu SP: Survivin inhibitor YM155 suppresses gastric cancer xenograft
growth in mice without affecting normal tissues. Oncotarget.
7:7096–7109. 2016.PubMed/NCBI
|
|
56
|
Cheng Q, Ling X, Haller A, Nakahara T,
Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F:
Suppression of survivin promoter activity by YM155 involves
disruption of Sp1-DNA interaction in the survivin core promoter.
Int J Biochem Mol Biol. 3:179–197. 2012.PubMed/NCBI
|
|
57
|
Clemens MR, Gladkov OA, Gartner E,
Vladimirov V, Crown J, Steinberg J, Jie F and Keating A: Phase II,
multicenter, open-label, randomized study of YM155 plus docetaxel
as first-line treatment in patients with HER2-negative metastatic
breast cancer. Breast Cancer Res Treat. 149:171–179. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kudchadkar R, Ernst S, Chmielowski B,
Redman BG, Steinberg J, Keating A, Jie F, Chen C, Gonzalez R and
Weber J: A phase 2, multicenter, open-label study of sepantronium
bromide (YM155) plus docetaxel in patients with stage III
(unresectable) or stage IV melanoma. Cancer Med. 4:643–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kelly RJ, Thomas A, Rajan A, Chun G,
Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et
al: A phase I/II study of sepantronium bromide (YM155, survivin
suppressor) with paclitaxel and carboplatin in patients with
advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Koike H, Nitta T, Sekine Y, Arai S, Furuya
Y, Nomura M, Matsui H, Shibata Y, Ito K, Oyama T and Suzuki K:
YM155 reverses rapamycin resistance in renal cancer by decreasing
survivin. J Cancer Res Clin Oncol. 140:1705–1713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Feng W, Yoshida A and Ueda T: YM155
induces caspase-8 dependent apoptosis through downregulation of
survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res
Commun. 435:52–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rivadeneira DB, Caino MC, Seo JH, Angelin
A, Wallace DC, Languino LR and Altieri DC: Survivin promotes
oxidative phosphorylation, subcellular mitochondrial repositioning,
and tumor cell invasion. Sci Signal. 8:ra802015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Glaros TG, Stockwin LH, Mullendore ME,
Smith B, Morrison BL and Newton DL: The ‘survivin suppressants’ NSC
80467 and YM155 induce a DNA damage response. Cancer Chemother
Pharmacol. 70:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tang H, Shao H, Yu C and Hou J: Mcl-1
downregulation by YM155 contributes to its synergistic anti-tumor
activities with ABT-263. Biochem Pharmacol. 82:1066–1072. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cheng SM, Chang YC, Liu CY, Lee JY, Chan
HH, Kuo CW, Lin KY, Tsai SL, Chen SH, Li CF, et al: YM155
down-regulates survivin and XIAP, modulates autophagy and induces
autophagy-dependent DNA damage in breast cancer cells. Br J
Pharmacol. 172:214–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng
L, Cao L, Xiao PF, Pang L, Wu D, et al: Survivin selective
inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC
Cancer. 12:6192012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang W, Liu Y, Li YF, Yue Y, Yang X and
Peng L: Targeting of survivin pathways by YM155 inhibits cell death
and invasion in oral squamous cell carcinoma cells. Cell Physiol
Biochem. 38:2426–2437. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tolcher AW, Mita A, Lewis LD, Garrett CR,
Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P,
et al: Phase I and pharmacokinetic study of YM155, a small-molecule
inhibitor of survivin. J Clin Oncol. 26:5198–5203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lewis KD, Samlowski W, Ward J, Catlett J,
Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R: A
multi-center phase II evaluation of the small molecule survivin
suppressor YM155 in patients with unresectable stage III or IV
melanoma. Invest New Drugs. 29:161–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Alexandrescu DT, Gonzales R, Lewis K,
Samlowski W, Cranmer L, Catlett J, Kirkwood J, Whitman E, Lawson D,
Bartels P, et al: A phase II study of YM155 administered as 168
hour continuous infusion in stage IV and unresectable stage III
melanoma. Mol Cancer Ther. 6:3385S. 2007.
|
|
72
|
Rauch A, Hennig D, Schäfer C, Wirth M,
Marx C, Heinzel T, Schneider G and Krämer OH: Survivin and YM155:
How faithful is the liaison? Biochim Biophys Acta. 1845:202–220.
2014.PubMed/NCBI
|
|
73
|
Ansell SM, Arendt BK, Grote DM, Jelinek
DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF and Fielding A:
Inhibition of survivin expression suppresses the growth of
aggressive non-Hodgkin's lymphoma. Leukemia. 18:616–623. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hanna N, Shepherd FA, Fossella FV, Pereira
JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, et al: Randomized phase III trial of pemetrexed versus
docetaxel in patients with non-small-cell lung cancer previously
treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Carrasco RA, Stamm NB, Marcusson E,
Sandusky G, Iversen P and Patel BK: Antisense inhibition of
survivin expression as a cancer therapeutic. Mol Cancer Ther.
10:221–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Henry SP, Geary RS, Yu R and Levin AA:
Drug properties of second-generation antisense oligonucleotides:
How do they measure up to their predecessors? Curr Opin Investig
Drugs. 2:1444–1449. 2001.PubMed/NCBI
|
|
77
|
Talbot DC, Ranson M, Davies J, Lahn M,
Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, et al:
Tumor survivin is downregulated by the antisense oligonucleotide
LY2181308: A proof-of-concept, first-in-human dose study. Clin
Cancer Res. 16:6150–6158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tanioka M1, Nokihara H, Yamamoto N, Yamada
Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S
and Tamura T: Phase I study of LY2181308, an antisense
oligonucleotide against survivin, in patients with advanced solid
tumors. Cancer Chemother Pharmacol. 68:505–511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Talbot DC, Davies J, Olsen A, Andre V,
Lahn M, Powell E, Kadam S, de Bono J, McHugh P and Ranson M:
Pharmacodynamic (PD) evaluation of LYPharmacodynamic (PD)
evaluation of LY2181308 in patients with metastatic malignancies. J
Clin Oncol. 27:35072009.
|
|
80
|
Plescia J, Salz W, Xia F, Pennati M,
Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, et
al: Rational design of shepherdin, a novel anticancer agent. Cancer
Cell. 7:457–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Young JC, Moarefi I and Hartl FU: Hsp90: A
specialized but essential protein-folding tool. J Cell Biol.
154:267–273. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hendruschk S, Wiedemuth R, Aigner A,
Töpfer K, Cartellieri M, Martin D, Kirsch M, Ikonomidou C,
Schackert G and Temme A: RNA interference targeting survivin exerts
antitumoral effects in vitro and in established glioma xenografts
in vivo. Neuro-Oncol. 13:1074–1089. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yang Z, Yu B, Zhu J, Huang X, Xie J, Xu S,
Yang X, Wang X, Yung BC, Lee LJ, et al: A microfluidic method to
synthesize transferrin-lipid nanoparticles loaded with siRNA
LOR-1284 for therapy of acute myeloid leukemia. Nanoscale.
6:9742–9751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Boukany PE, Morss A, Liao WC, Henslee B,
Jung H, Zhang X, Yu B, Wang X, Wu Y, Li L, et al: Nanochannel
electroporation delivers precise amounts of biomolecules into
living cells. Nat Nanotechnol. 6:747–754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wen Y and Meng WS: Recent in vivo
evidences of particle-based delivery of small-interfering RNA
(siRNA) into solid tumors. J Pharm Innov. 9:158–173. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Devi GR: siRNA-based approaches in cancer
therapy. Cancer Gene Ther. 13:819–829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish
N, Adami R, Harvie P, Johns R, Severson G, Brown T, et al:
RNAi-based therapeutics targeting survivin and PLK1 for treatment
of bladder cancer. Mol Ther. 19:928–935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lee SJ, Son S, Yhee JY, Choi K, Kwon IC,
Kim SH and Kim K: Structural modification of siRNA for efficient
gene silencing. Biotechnol Adv. 31:491–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zheng J, Zhang L, Zhang J, Wang X, Ye K,
Xi Z, Du Q and Liang Z: Single modification at position 14 of siRNA
strand abolishes its gene-silencing activity by decreasing both
RISC loading and target degradation. FASEB J. 27:4017–4026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Dykxhoorn DM and Lieberman J: Knocking
down disease with siRNAs. Cell. 126:231–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sahay G, Querbes W, Alabi C, Eltoukhy A,
Sarkar S, Zurenko C, Karagiannis E, Love K, Chen D, Zoncu R, et al:
Efficiency of siRNA delivery by lipid nanoparticles is limited by
endocytic recycling. Nat Biotechnol. 31:653–658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Perez AP, Cosaka ML, Romero EL and Morilla
MJ: Uptake and intracellular traffic of siRNA dendriplexes in
glioblastoma cells and macrophages. Int J Nanomedicine.
6:2715–2728. 2011.PubMed/NCBI
|
|
94
|
Mamori S, Matsushima M, Matsuura T and
Tajiri H: Survivin is expressed in early hepatocellular carcinoma
and surrounding hepatitis tissue. Mol Med Rep. 2:911–915. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Shariat SF, Lotan Y, Saboorian H, Khoddami
SM, Roehrborn CG, Slawin KM and Ashfaq R: Survivin expression is
associated with features of biologically aggressive prostate
carcinoma. Cancer. 100:751–757. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ferrandina G, Legge F, Martinelli E,
Ranelletti FO, Zannoni GF, Lauriola L, Gessi M, Gallotta V and
Scambia G: Survivin expression in ovarian cancer and its
correlation with clinico-pathological, surgical and
apoptosis-related parameters. Br J Cancer. 92:271–277. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Shinohara ET, Gonzalez A, Massion PP, Chen
H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, et
al: Nuclear survivin predicts recurrence and poor survival in
patients with resected nonsmall cell lung carcinoma. Cancer.
103:1685–1692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Nasu S, Yagihashi A, Izawa A, Saito K,
Asanuma K, Nakamura M, Kobayashi D, Okazaki M and Watanabe N:
Survivin mRNA expression in patients with breast cancer. Anticancer
Res. 22:1839–1843. 2002.PubMed/NCBI
|
|
99
|
Yu J, Leung WK, Ebert MP, Ng EK, Go MY,
Wang HB, Chung SC, Malfertheiner P and Sung JJ: Increased
expression of survivin in gastric cancer patients and in first
degree relatives. Br J Cancer. 87:91–97. 2002. View Article : Google Scholar : PubMed/NCBI
|
